Company Information

Get to know Inventiva

Inventiva is a French biopharmaceutical company specializing in the research and development of innovative treatments, primarily for non-alcoholic steatohepatitis (NASH) and other fibrotic diseases. Founded in 2012 following a spin-off from Abbott's research division, the company leverages its expertise in nuclear receptors, transcription factors, and epigenetic modulation. Its lead drug candidate, lanifibranor, is in late-stage clinical trials for the treatment of NASH. Inventiva is publicly traded on the Euronext Paris stock exchange and on the NASDAQ Global Market.

Industry

Financial FundraisingPRIMARY
Financial Other Service

Contact

Social

THIS SERVICE IS NOT AVAILABLE IN YOUR REGION

Inventiva

India

Founded in

21 1月 2017 (9 Years)

Founded

Last online: No recent activity

Claim company Visit website

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

OVERALL SCORE

Others

--/10

Reviews

--/90

0 reviews

Provided by TrustFinance

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.

Markets.com

(327 reviews)

United States

2008

(18 years)

Security Information :

FSCA

Security Information

Warning

This company is currently Unproved.

Please be cautious of the potential risks!

License

A Grade License

Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.

B Grade License

Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.

C Grade License

Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.

D Grade License

From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.

TrustFinance is not a licensed financial advisor and is not affiliated with any financial institutions in your region. We encourage you to do your own research before making any investment decisions.